{"id":32679,"date":"2025-04-29T14:39:09","date_gmt":"2025-04-29T06:39:09","guid":{"rendered":"https:\/\/flcube.com\/?p=32679"},"modified":"2025-04-29T14:39:09","modified_gmt":"2025-04-29T06:39:09","slug":"regenerons-lynozyfic-gains-ec-conditional-approval-for-relapsed-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32679","title":{"rendered":"Regeneron’s Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma"},"content":{"rendered":"\n

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN<\/a>) announced that it has received conditional marketing authorization from the European Commission (EC) for its bispecific antibody (BsAb) Lynozyfic (linvoseltamab). The therapy is approved for adult patients with relapsed and refractory multiple myeloma (R\/R MM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and whose disease has progressed on the last treatment.<\/p>\n\n\n\n

Therapeutic Innovation and Adaptive Regimen<\/strong>
Lynozyfic is the first BCMAxCD3 bispecific antibody approved in Europe with a response-adapted regimen. Patients achieving a very good partial response (VGPR) or better after completing at least 24 weeks of therapy may transition to dosing every four weeks. This adaptive dosing approach aims to optimize treatment efficacy and patient convenience.<\/p>\n\n\n\n

Clinical Trial Data Supporting Approval<\/strong>
The approval is supported by data from the pivotal LINKER-MM1 trial (200 mg cohort, n=117). Key results include a 71% objective response rate (ORR) by independent review, with 50% of patients achieving a complete response (CR) or better. Additionally, a 41% minimal residual disease (MRD) negativity rate was observed among CR\/stringent CR patients (24\/58; 95% CI: 29\u201355%), and the median duration of response (DOR) was 29 months (95% CI: 19\u2013NE). These results highlight Lynozyfic’s potential to significantly improve outcomes for patients with advanced multiple myeloma.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received conditional marketing authorization from the…<\/p>\n","protected":false},"author":1,"featured_media":32681,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,1166,15,1426,2790],"class_list":["post-32679","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-nasdaq-regn","tag-product-approvals","tag-regeneron-pharmaceuticals","tag-t-cell-engager"],"yoast_head":"\nRegeneron's Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received conditional marketing authorization from the European Commission (EC) for its bispecific antibody (BsAb) Lynozyfic (linvoseltamab). The therapy is approved for adult patients with relapsed and refractory multiple myeloma (R\/R MM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and whose disease has progressed on the last treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32679\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron's Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma\" \/>\n<meta property=\"og:description\" content=\"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received conditional marketing authorization from the European Commission (EC) for its bispecific antibody (BsAb) Lynozyfic (linvoseltamab). The therapy is approved for adult patients with relapsed and refractory multiple myeloma (R\/R MM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and whose disease has progressed on the last treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32679\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-29T06:39:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2910.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32679#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32679\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Regeneron’s Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma\",\"datePublished\":\"2025-04-29T06:39:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32679\"},\"wordCount\":225,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32679#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2910.webp\",\"keywords\":[\"Cancer\",\"NASDAQ: REGN\",\"Product approvals\",\"Regeneron Pharmaceuticals\",\"T cell engager\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32679#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32679\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32679\",\"name\":\"Regeneron's Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32679#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32679#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2910.webp\",\"datePublished\":\"2025-04-29T06:39:09+00:00\",\"description\":\"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received conditional marketing authorization from the European Commission (EC) for its bispecific antibody (BsAb) Lynozyfic (linvoseltamab). The therapy is approved for adult patients with relapsed and refractory multiple myeloma (R\\\/R MM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and whose disease has progressed on the last treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32679#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32679\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32679#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2910.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2910.webp\",\"width\":1080,\"height\":608,\"caption\":\"egeneron's Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32679#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron’s Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Regeneron's Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma - Insight, China's Pharmaceutical Industry","description":"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received conditional marketing authorization from the European Commission (EC) for its bispecific antibody (BsAb) Lynozyfic (linvoseltamab). The therapy is approved for adult patients with relapsed and refractory multiple myeloma (R\/R MM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and whose disease has progressed on the last treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32679","og_locale":"en_US","og_type":"article","og_title":"Regeneron's Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma","og_description":"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received conditional marketing authorization from the European Commission (EC) for its bispecific antibody (BsAb) Lynozyfic (linvoseltamab). The therapy is approved for adult patients with relapsed and refractory multiple myeloma (R\/R MM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and whose disease has progressed on the last treatment.","og_url":"https:\/\/flcube.com\/?p=32679","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-29T06:39:09+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2910.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32679#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32679"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Regeneron’s Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma","datePublished":"2025-04-29T06:39:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32679"},"wordCount":225,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32679#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2910.webp","keywords":["Cancer","NASDAQ: REGN","Product approvals","Regeneron Pharmaceuticals","T cell engager"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32679#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32679","url":"https:\/\/flcube.com\/?p=32679","name":"Regeneron's Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32679#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32679#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2910.webp","datePublished":"2025-04-29T06:39:09+00:00","description":"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received conditional marketing authorization from the European Commission (EC) for its bispecific antibody (BsAb) Lynozyfic (linvoseltamab). The therapy is approved for adult patients with relapsed and refractory multiple myeloma (R\/R MM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and whose disease has progressed on the last treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32679#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32679"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32679#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2910.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2910.webp","width":1080,"height":608,"caption":"egeneron's Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32679#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Regeneron’s Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2910.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32679"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32679\/revisions"}],"predecessor-version":[{"id":32682,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32679\/revisions\/32682"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32681"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}